n.a. (ARIA)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
Cramer's Top Stock Picks: ARIA ALKS LINE KORS WFM

Cramer's Top Stock Picks: ARIA ALKS LINE KORS WFM

It's time to think more favorably of Michael Kors and Whole Foods, Cramer said, and Linn is taking advantage of the energy boom.

Cramer's 'Mad Money' Recap: I Told You So

Cramer's 'Mad Money' Recap: I Told You So

Today's rally showed how wrong the bears were during the market selloff seven days ago.

ARIAD Reports 2012 Financial Results And Outlines Key Objectives For 2013

ARIAD Reports 2012 Financial Results And Outlines Key Objectives For 2013

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the fourth quarter and full year ended December 31, 2012 and provided an update on corporate developments.

Jonathan E. Dickinson, General Manager, ARIAD Pharmaceuticals (Europe), Sàrl (Photo: Business Wire)

Jonathan E. Dickinson, General Manager, ARIAD Pharmaceuticals (Europe), Sàrl (Photo: Business Wire)

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the appointment of Jonathan E.

ARIAD To Present At The RBC Capital Markets Healthcare Conference

ARIAD To Present At The RBC Capital Markets Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the RBC Capital Markets Healthcare Conference being held in New York City.

Ariad Pharmaceuticals (ARIA): Today's Featured Health Care Winner

Ariad Pharmaceuticals (ARIA): Today's Featured Health Care Winner

Ariad Pharmaceuticals was a winner within the health care sector, rising 43 cents (2.2%) to $20.03 on average volume.

ARIAD To Present At The Leerink Swann Global Healthcare Conference

ARIAD To Present At The Leerink Swann Global Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Leerink Swann Global Healthcare Conference being held in New York City.

ARIAD To Webcast Conference Call On Fourth Quarter And Year-End 2012 Financial Results

ARIAD To Webcast Conference Call On Fourth Quarter And Year-End 2012 Financial Results

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will host a live webcast of its quarterly conference call at 8:30 a.

ARIAD Announces Completion Of Public Offering

ARIAD Announces Completion Of Public Offering

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the completion of its previously announced public offering of 15,307,000 shares of common stock at a public offering price of $19.

Ariad Stock Falls On Unusually High Volume (ARIA)

Ariad Stock Falls On Unusually High Volume (ARIA)

Ariad Pharmaceuticals (Nasdaq:ARIA) is trading at unusually high volume Thursday with 5.2 million shares changing hands. It is currently at two times its average daily volume and trading down 42 cents (-2.1%).

ARIAD Announces Pricing Of Public Offering Of Common Stock

ARIAD Announces Pricing Of Public Offering Of Common Stock

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the pricing of an underwritten public offering of 15,307,000 shares of its common stock, at a price to the public of $19.

Ariad Pharmaceuticals (ARIA): Today's Featured Drugs Laggard

Ariad Pharmaceuticals (ARIA): Today's Featured Drugs Laggard

Ariad Pharmaceuticals was a leading decliner within the drugs industry, falling 36 cents (-1.7%) to $20.38 on average volume.

J.P. Morgan Healthcare Confab Live Blog: Day One

J.P. Morgan Healthcare Confab Live Blog: Day One

Live, interactive coverage of the biotech and drug companies presenting at the J.P. Morgan Healthcare Conference.

(Graphic: Business Wire)

(Graphic: Business Wire)

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) and Newcastle University, U.

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

Biotech 2013 Kickoff Party: J.P. Morgan Investor Confab

A preview of what to expect from biotech stocks at the next week's 'Life Sciences Lollapalooza.'

ARIAD To Present At The 31st Annual J.P. Morgan Healthcare Conference

ARIAD To Present At The 31st Annual J.P. Morgan Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the 31st Annual J.

Ariad Stock Falls On Unusually High Volume (ARIA)

Ariad Stock Falls On Unusually High Volume (ARIA)

Ariad Pharmaceuticals (Nasdaq:ARIA) is trading at unusually high volume Friday with 4.2 million shares changing hands. It is currently at 2.1 times its average daily volume and trading down $2.12 (-8.9%).

The Iclusig™ Bottle (Photo: Business Wire)

The Iclusig™ Bottle (Photo: Business Wire)

Please replace the release with the following corrected version due to revisions in the Important Safety Information section and the addition of an embedded link to the “Prescribing Information.

FDA Approves Ariad Pharma Leukemia Drug

FDA Approves Ariad Pharma Leukemia Drug

The FDA's approval of Iclusig comes three months earlier than expected.

ARIAD Announces 12-Month Data From Pivotal PACE Trial Of Ponatinib In Heavily Pretreated Patients With Advanced-Phase CML And Ph+ ALL

ARIAD Announces 12-Month Data From Pivotal PACE Trial Of Ponatinib In Heavily Pretreated Patients With Advanced-Phase CML And Ph+ ALL

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced twelve-month follow-up data from the pivotal PACE trial of ponatinib, its investigational BCR-ABL inhibitor, in heavily pretreated patients with...

ARIAD Announces Long-Term Molecular Response Data On Ponatinib

ARIAD Announces Long-Term Molecular Response Data On Ponatinib

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced updated molecular response data from its Phase 1 and pivotal Phase 2 trials of ponatinib, its investigational BCR-ABL inhibitor, in heavily pretreated ...

Best Biotech CEO of 2012: Your Vote Counts

Best Biotech CEO of 2012: Your Vote Counts

CEOs from Onyx Pharma, Gilead Sciences, Regeneron Pharma and Sarepta Therapeutics vie for title.

ARIAD Announces 12-Month Data From Pivotal PACE Trial Of Ponatinib In Heavily Pretreated Chronic-Phase CML Patients

ARIAD Announces 12-Month Data From Pivotal PACE Trial Of Ponatinib In Heavily Pretreated Chronic-Phase CML Patients

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced twelve-month follow-up data from the pivotal PACE trial of ponatinib, its investigational BCR-ABL inhibitor, in heavily pretreated patients with...

ARIAD Announces Ponatinib Presentations At Annual American Society Of Hematology Meeting

ARIAD Announces Ponatinib Presentations At Annual American Society Of Hematology Meeting

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced the presentations on ponatinib, its investigational BCR-ABL inhibitor, that will take place at the 54th Annual Meeting of the American Society of ...

5 Stocks About to Burst

5 Stocks About to Burst

Trading stocks that trigger major breakouts can lead to massive profits.

The Ponatinib Molecule Fitting Into The Binding Pocket Of BCR-ABL, An Abnormal Enzyme That Drives Chronic Myeloid Leukemia (CML) And Philadelphia-chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). (Graphic: Business Wire)

The Ponatinib Molecule Fitting Into The Binding Pocket Of BCR-ABL, An Abnormal Enzyme That Drives Chronic Myeloid Leukemia (CML) And Philadelphia-chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). (Graphic: Business Wire)

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced publication of results from the Phase 1 study of ponatinib, its investigational, tyrosine kinase inhibitor in heavily pretreated patients with resistant...

Http://ariad.com

Http://ariad.com

Foundation Medicine, Inc. and ARIAD Pharmaceuticals, Inc.

Ariad Pharmaceuticals Stock Downgraded (ARIA)

Ariad Pharmaceuticals Stock Downgraded (ARIA)

Ariad Pharmaceuticals (Nasdaq:ARIA) has been downgraded by TheStreet Ratings from from a hold to sell.

ARIAD To Present At The Lazard Capital Markets Healthcare Conference

ARIAD To Present At The Lazard Capital Markets Healthcare Conference

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that it will present at the Lazard Capital Markets 9 th Annual Healthcare Conference being held in New York City.

ARIAD Reports Third Quarter 2012 Financial Results And Development Progress

ARIAD Reports Third Quarter 2012 Financial Results And Development Progress

ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the third quarter and nine months ended September 30, 2012 and provided an update on corporate developments.